Scarica l'app Stockscreener
429.18
1.51%
-6.60
Dopo l'orario di chiusura:
430.00
0.82
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$435.78
Aprire:
$430.14
Volume 24 ore:
279.20K
Relative Volume:
0.79
Capitalizzazione di mercato:
$9.53B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-17.09
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
-0.19%
1M Prestazione:
+1.17%
6M Prestazione:
+29.55%
1 anno Prestazione:
+97.78%
Intervallo 1D:
$426.65
$435.00
Intervallo di 1 settimana:
$413.82
$436.84
Portata 52W:
$213.71
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
429.18 | 9.71B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 - The Manila Times
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Madrigal (NASDAQ: MDGL) to present cirrhosis and real-world Rezdiffra data at AASLD 2025 - Stock Titan
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsBond Market & Capital Efficiency Focused Ideas - newser.com
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Value Report & Consistent Income Trade Recommendations - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againJuly 2025 Sector Moves & Stock Portfolio Risk Management - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.Quarterly Investment Review & Precise Buy Zone Identification - newser.com
How forex fluctuations impact Madrigal Pharmaceuticals Inc. (YDO1) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis toolsMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock profit from AI boom2025 Earnings Impact & Daily Chart Pattern Signals - Fundação Cultural do Pará
Is it too late to sell Madrigal Pharmaceuticals Inc.Quarterly Risk Review & Low Drawdown Trading Strategies - newser.com
Madrigal Pharmaceuticals set to unveil Q3 2025 financial results on November 4 - Traders Union
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.July 2025 Review & Daily Technical Forecast Reports - newser.com
Is Madrigal Pharmaceuticals Inc a good long term investmentProtective Put Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bode Well For Continued Growth MDGL - Seeking Alpha
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.28%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):